New Frontiers in the Treatment and Management of Chronic Lymphocytic Leukemia (CLL): Expert Perspectives on Emerging Therapies and MRD

A continuing medical education activity sponsored by NAMCP and AAMCN.

This activity is an archive from the live session from the 2020 Spring Managed Care Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive

This activity is valid from May 1, 2020 to May 1, 2021

Instructions for CME/CNE: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.

 

Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This presentation is supported by educational grants from
AbbVie, Adaptive Biotechnologies, AstraZeneca, BieGene, and Verastem Oncology

Description:
Chronic lymphocytic leukemia (CLL) is a cancer of the blood and bone marrow that affects older adults. It affects B cell lymphocytes, which originate in the bone marrow, develop in the lymph nodes, and normally fight infection by producing antibodies. Patients with CLL are often diagnosed when they are asymptomatic; therefore, knowing when to initiate treatment may pose a challenge to clinicians. Furthermore, patients with CLL have impaired immune systems and multiple comorbidities, which can complicate management and impact treatment decisions. While generally considered incurable, CLL progresses slowly in most cases and treatment focuses on controlling the disease and its symptoms. Fortunately, new combination regimens have recently become available that have shown the ability to greatly improve outcomes in previously untreated CLL.

Upon completion of this activity, participants will be able to:

  • Explore the latest clinical evidence surrounding current and emerging targeted therapies for CLL, distinguishing among mechanism of action, efficacy in distinct patient populations, adverse event profiles, and long-term data

  • Analyze the role of next generation BTK inhibitors in the management of CLL

  • Explore the role of new and emerging PI3K inhibitors in the management of relapsed/refractory CLL

  • Describe the advantages and limitations of measuring minimal residual disease (MRD) in CLL

  • Articulate the rationale for using MRD negativity as a new outcomes goal of treatment as well as an endpoint for clinical trials in CLL

  • Discuss managed care considerations of new and emerging targeted therapies and MRD-monitoring tests by exploring where these agents and tests fit into current CLL management paradigm
     

Faculty: John N. Allan, MD
Assistant Professor of Medicine
Division of Hematology and Medical Oncology
Weill Cornell Medical College

Disclosure:

Dr. Allan has served on an advisory board for AbbVie, Ascentage, Cellactar, Genentech, Janssen, and Pharmacyclics. He serves as a consultant for AbbVie, AstraZeneca, and Janssen. He has received grant/research support from Celgene, Genentech, and Janssen. He serves on the speaker's bureau for AbbVie, Janssen, and Pharmacyclics. His presentation has been peer reviewed for any bias.
  Planning Committee:
Bill Williams, MD has no relevant financial relationships to disclose.
Jeremy Williams has no relevant financial relationships to disclose.
Will Williams has no relevant financial relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no relevant financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the National Association of Managed Care Physicians (NAMCP) and American Association of Managed Care Nurses (AAMCN). The National Association of Managed Care Physicians is accredited by the ACCME to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their participation in the activity.

The American Association of Managed Care Nurses is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in continuing
nursing credit.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This presentation is supported by educational grants from
AbbVie, Adaptive Biotechnologies, AstraZeneca, BieGene, and Verastem Oncology

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue